What Spirosure does

Spirosure (firmographic header) is described as a developer of breath-analysis devices for disease diagnosis and management, founded in 2011 in Pleasanton, California with a small team (1–10 employees). The substantive operational data available, however, describes what appears to be a much larger affiliated entity, CAIRE Inc., a Niterra (formerly NGK Spark Plug) subsidiary headquartered in Ball Ground, Georgia. That entity develops and manufactures cardiorespiratory diagnostic systems and oxygen therapy solutions, including the FreeStyle Comfort portable oxygen concentrator with autoSAT auto-adjustment technology, the Fenom Flo™ portable FeNO monitoring system (a 6-second breath test for respiratory diagnostics), VPSA and PSA onsite oxygen generation systems for industrial customers, liquid oxygen systems, and the Centrox-CR oxygen cylinder refilling station for emergency medical services.

CAIRE's product portfolio spans two primary verticals: Medical/Healthcare (hospitals, clinics, EMS, and chronic respiratory patients requiring oxygen therapy or FeNO-based diagnostics) and Commercial/Industrial (onsite VPSA/PSA oxygen generation for facilities needing continuous supply). The company holds multiple registered trademarks (CAIRE®, AirSep®, FreeStyle Comfort®, Fenom Flo™, Centrox-CR™) and operates wholly-owned sub-brands including MGC Diagnostics (cardiorespiratory diagnostics) and AirSep (oxygen therapy). Go-to-market is conducted through authorized distributor and service networks (e.g., Sunset Healthcare Solutions for Canada), with channel partners handling regional sales, installation, and ongoing maintenance.

The company's funding history — approximately $41 million across three rounds from 2014, 2016, and 2018, led by NGK Spark Plug (now Niterra) and Fosun Pharma — places it within the Niterra corporate group, which provides strategic backing and a probable operating backbone. Notable recent commercial activity includes the October 2025 U.S. launch of the FreeStyle Comfort with autoSAT, the February 2026 U.S. introduction of the Fenom Flo, and a June 2026 Canadian distribution and service-network expansion. The company does not publicly disclose pricing, revenue, or unit-shipment figures.

A material data integrity note: the firmographic header identifies the subject as Spirosure (Pleasanton, founded 2011, breath-analysis devices, 1–10 employees), whereas the bulk of operational evidence describes CAIRE Inc. (Ball Ground, GA, Niterra subsidiary, multi-product oxygen and diagnostics portfolio). The two share an investor (NGK Spark Plug / Niterra), which likely accounts for cross-contamination in the dataset. The description above reflects the operational evidence available; readers should treat firmographic and operational fields as potentially inconsistent.

Name

Spirosure

Legal name

CAIRE Inc.

Website

https://spirosure.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Spirosure is described as a developer of breath-analysis devices for disease diagnosis and management, founded in 2011 in Pleasanton, California; the available operational evidence profiles a Niterra-affiliated oxygen therapy and cardiorespiratory diagnostics business serving medical and industrial customers globally through authorized distributor networks.

Ownership category

akta.pro rank

Product category

Medical Devices - Respiratory Diagnostics & Oxygen Therapy

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Pulmonary Function Testing (PFT) & Spirometry Equipment (HLAHAGAH)

akta.pro secondary industry

Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI)

Keywords

• Breath analysis devices
• Oxygen therapy systems
• Cardiorespiratory diagnostics
• Portable oxygen concentrators
• Medical oxygen generation

Headquarters

HQ city

Pleasanton

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Distribution channels2 records

Marketing channels1 record

Core offering

Spirosure develops breath-analysis devices for disease diagnosis and management. The company, operating through its CAIRE Inc. subsidiary, manufactures and sells cardiorespiratory diagnostic systems, portable and stationary oxygen concentrators, liquid oxygen systems, and on-site VPSA/PSA oxygen generation solutions for medical and commercial customers.

Product overview

CAIRE Inc., a Niterra company, offers a comprehensive portfolio of cardiorespiratory diagnostic systems and oxygen therapy solutions. The product portfolio includes MGC Diagnostics for cardiorespiratory diagnostics (featuring the Fenom Flo™ portable FeNO monitoring system), portable oxygen concentrators like the award-winning FreeStyle Comfort with autoSAT technology, VPSA and PSA onsite oxygen generation solutions, and the Centrox-CR oxygen cylinder refilling station. The company operates across medical (diagnostics and oxygen therapy) and commercial application segments.

Differentiator

Problem solved

Functional benefit

Brands

• Fenom Flo: Portable FeNO monitoring system for breath testing
• FreeStyle Comfort
• Centrox-CR

Products and services

• MGC Diagnostics A wholly-owned subsidiary brand providing cardiorespiratory diagnostic systems, offering clinical testing equipment for pulmonary function and respiratory analysis.
• Fenom Flo™ Portable FeNO (Fractional Exhaled Nitric Oxide) monitoring system approved for a 6-second breath test, used for respiratory diagnostics.
• FreeStyle Comfort Award-winning portable oxygen concentrator with autoSAT technology that auto-adjusts with every breath for personalized oxygen delivery.
• Centrox-CR Oxygen cylinder refilling station for Emergency Medical Services, enabling on-site refilling of oxygen cylinders.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• Sunset Healthcare SolutionscoreChannel Partner/ Reseller/ Distributor · 24 June 2026Sunset Healthcare Solutions appointed as Canadian distributor for CAIRE products, expanding distribution reach in Canada.
• MGC DiagnosticscoreStrategic or Co-development PartnerMGC Diagnostics is part of CAIRE Inc., providing cardiorespiratory diagnostic systems including the Fenom Flo portable FeNO monitoring system.
• NiterracoreOthersCAIRE Inc. is a subsidiary of Niterra as evidenced by the CAIRE-Niterra logo on the corporate website.

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• ResMed: ResMed is a global leader in sleep-disordered breathing and respiratory care, with a portfolio spanning PAP devices, ventilators, and connected health. It is a broad incumbent in the respiratory care ecosystem in which Spirosure/CAIRE participates via diagnostics and oxygen therapy.
• Chart Industries: Chart Industries provides medical and industrial gas handling, including onsite oxygen generation (PSA/VPSA), oxygen therapy equipment, and respiratory products. Its medical portfolio directly overlaps CAIRE's VPSA/PSA onsite generation and respiratory offerings adjacent to Spirosure's products.
• Philips Respiratory Care: Philips offers a broad respiratory portfolio including hospital ventilators, oxygen therapy, and respiratory diagnostics. It competes with CAIRE's hospital/clinical oxygen therapy and diagnostic offerings, providing a broad incumbent benchmark.

Direct peers

• ndd Medical Technologies: ndd Medical Technologies is a specialist in pulmonary function testing, including ultrasonic spirometry and FeNO devices. Its EasyOne-series PFT products compete with the broader MGC Diagnostics/CAIRE respiratory diagnostics portfolio that includes Fenom Flo.
• Vitalograph: Vitalograph manufactures pulmonary function testing and respiratory diagnostic devices used by clinicians and occupational health providers. Its spirometry and PFT portfolio overlaps with the diagnostic workflows where Fenom Flo is deployed.
• NIOX (Circassia Group): NIOX is the established global leader in fractional exhaled nitric oxide (FeNO) monitoring for asthma and airway inflammation diagnosis. Its NIOX VERO and NIOX MINO devices compete directly with Spirosure's Fenom Flo in the same clinical use case and customer base.
• COSMED: COSMED designs and manufactures cardiorespiratory diagnostic and metabolic testing equipment, including pulmonary function and indirect calorimetry systems used in hospitals and research settings. Its Quark product line competes with MGC Diagnostics platforms that house Spirosure's breath-analysis offering.

Others

• CAIRE Inc. CAIRE Inc. is Spirosure's parent company (a Niterra subsidiary) and operates the MGC Diagnostics brand under which the Fenom Flo product is commercialized. CAIRE shares the cardiorespiratory diagnostic and oxygen therapy portfolio that Spirosure's breath-analysis technology plugs into.
• MGC Diagnostics: MGC Diagnostics is a wholly-owned subsidiary/brand within CAIRE Inc. and provides the cardiorespiratory diagnostic systems through which Spirosure's Fenom Flo is commercialized. It is the immediate commercial vehicle rather than a competitor.

Emerging players

• Inogen: Inogen is a pure-play portable oxygen concentrator company competing with CAIRE's FreeStyle Comfort and broader oxygen therapy portfolio. While not a direct FeNO competitor, Inogen operates in the same chronic respiratory patient ecosystem that Spirosure/CAIRE serves.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/spirometrix
• LinkedInlinkedin.com/company/spirometrix-inc-

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spirosure